Radiology Department, Arkansas Children's Hospital and University of Arkansas for Medical Sciences, Slot 105, 1 Children's Way, Little Rock, AR, 72202, USA.
Quality, Risk, and Safety Department, Arkansas Children's Hospital, Little Rock, AR, USA.
Pediatr Radiol. 2022 Nov;52(12):2413-2420. doi: 10.1007/s00247-022-05365-z. Epub 2022 Apr 22.
While chest tube placement with pleural fibrinolytic medication is the established treatment of pediatric empyema, treatment failure is reported in up to 20% of these children.
Standardizing fibrinolytic administration among interventional radiology (IR) physicians to improve patient outcomes in pediatric parapneumonic effusion.
We introduced a hospital-wide clinical pathway for parapneumonic effusion (1-2 mg tissue plasminogen activator [tPA] twice daily based on pleural US grade); we then collected prospective data for IR treatment May 2017 through February 2020. These data included demographics, co-morbidities, pediatric intensive care unit (PICU) admission, pleural US grade, culture results, daily tPA dose average, twice-daily dose days, skipped dose days, pleural therapy days, need for chest CT/a second IR procedure/surgical drainage, and length of stay. We compared the prospective data to historical controls with IR treatment from January 2013 to April 2017.
Sixty-three children and young adults were treated after clinical pathway implementation. IR referrals increased (P = 0.02) and included higher co-morbidities (P = 0.005) and more PICU patients (P = 0.05). Mean doses per day increased from 1.5 to 1.9 (P < 0.001), twice-daily dose days increased from 38% to 79% (P < 0.001) and median pleural therapy days decreased from 3.5 days to 2.5 days (P = 0.001). No IR patients needed surgical intervention. No statistical differences were observed for gender/age/weight, US grade, need for a second IR procedure or length of stay. US grade correlated with greater positive cultures, need for chest CT/second IR procedure, and pleural therapy days.
Interventional radiology physician standardization improved on a clinical pathway for fibrinolysis of parapneumonic effusion. Despite higher patient complexity, pleural therapy duration decreased. There were no chest tube failures needing surgical drainage.
尽管胸腔引流管置管联合胸膜纤维蛋白溶解药物治疗是小儿脓胸的既定治疗方法,但据报道,多达 20%的患儿治疗失败。
在介入放射科 (IR) 医生中标准化纤维蛋白溶解药物的使用,以改善小儿类肺炎性胸腔积液患者的治疗效果。
我们引入了一个针对类肺炎性胸腔积液的全院临床路径(根据胸腔超声分级,每天给予 1-2mg 组织型纤溶酶原激活物[ tPA] 两次);然后收集 2017 年 5 月至 2020 年 2 月间 IR 治疗的前瞻性数据。这些数据包括人口统计学特征、合并症、小儿重症监护病房(PICU)入院、胸腔超声分级、培养结果、每日 tPA 剂量平均值、每日两次剂量天数、漏用剂量天数、胸腔治疗天数、是否需要胸部 CT/再次 IR 操作/外科引流以及住院时间。我们将前瞻性数据与 2013 年 1 月至 2017 年 4 月间接受 IR 治疗的历史对照数据进行了比较。
在临床路径实施后,共有 63 名儿童和青少年接受了治疗。IR 转介增加(P=0.02),且合并症更多(P=0.005),更多患者进入 PICU(P=0.05)。每日平均剂量从 1.5 增加到 1.9(P<0.001),每日两次剂量天数从 38%增加到 79%(P<0.001),中位胸腔治疗天数从 3.5 天减少到 2.5 天(P=0.001)。没有 IR 患者需要手术干预。在性别/年龄/体重、超声分级、是否需要再次 IR 操作或住院时间方面,两组之间没有统计学差异。超声分级与阳性培养物的存在、是否需要胸部 CT/再次 IR 操作以及胸腔治疗天数相关。
IR 医生的标准化操作改进了类肺炎性胸腔积液纤维蛋白溶解的临床路径。尽管患者的复杂性增加,但胸腔治疗时间缩短。没有因胸腔引流管堵塞需要手术引流的病例。